Skip to main content

Table 1 Characteristics of the full study population and ER+ and ER- subgroups

From: Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

  Full population ER+ cases ER- cases
n a 2006 1620 386
Baseline characteristics, median (range), or n (%))
 Age at blood collection, years 56.6 (26.7, 75.5) 56.8 (33.4, 75.5) 54.9 (26.7, 72.1)
 Age at menarche, years* 13.0 (8.0, 20.0) 13.0 (8.0, 20.0) 13.0 (9.0, 20.0)
Menopausal status at blood collection
  Premenopausal 463 (23%) 352 (22%) 111 (29%)
  Postmenopausal 1543 (77%) 1268 (78%) 275 (71%)
   PMH use at blood collectionb 753 (49%) 623 (49%) 130 (47%)
   Age at menopause, yearsb* 50.0 (27.0, 63.0) 50.0 (27.0, 63.0) 49.0 (30.0, 59.0)
Full term pregnancy, ever* 1693 (86%) 1356 (85%) 337 (89%)
  Age at first term pregnancy, yearsc* 25.0 (16.0, 44.0) 25.0 (16.0, 44.0) 24.0 (16.0, 38.0)
BMI, kg/m2 24.4 (13.8, 49.1) 24.5 (13.8, 49.1) 24.0 (16.6, 45.4)
sRANKL concentrations (pmol/L)a 0.11 (0.005, 1.67) 0.11 (0.005, 1.67) 0.11 (0.005, 0.58)
OPG concentrations (pmol/L) 9.86 (2.96, 31.97) 9.95 (2.96, 31.97) 9.59 (3.14, 21.38)
sRANKL/OPG ratio a 0.01 (0.0002, 0.17) 0.01 (0.0002, 0.17) 0.01 (0.0002, 0.09)
Breast cancer characteristics
 Age at diagnosis, years 60.9 (35.2, 83.6) 61.3 (37.1, 83.6) 59.1 (35.2, 80.6)
 Time between blood collection and diagnosis, years 4.7 (0.02, 11.7) 4.8 (0.02, 12.0) 4.5 (0.04, 11.5)
Progesterone receptor subtype at diagnosis*
  PR+ 984 (67%) 926 (80%) 58 (18%)
  PR- 494 (33%) 236 (20%) 258 (82%)
Breast cancer stage at diagnosis*
  Localized 1089 (68%) 877 (68%) 212 (66%)
  Non-localizedd 524 (32%) 415 (32%) 109 (34%)
Deaths & follow-up
 Number of deaths of any cause 421 (21.0%) 310 (19%) 111 (29%)
 Number of breast cancer deaths 250 (12.5%) 165 (10%) 85 (22%)
 Duration of follow-up, yearse 10.9 (0.05, 19.1) 11.0 (0.05, 19.1) 10.3 (0.08, 18.3)
 Overall survival time, yearsf 6.5 (0.08, 18.5) 7.2 (0.14, 18.5) 4.1 (0.08, 15.2)
 Breast cancer-specific survival time, yearsg 5.0 (0.8, 15.2) 6.4 (0.7, 14.8) 3.4 (0.08, 15.2)
  1. an = 1970 for sRANKL analyses and n = 1965 for sRANKL/OPG ratio analyses, comparable distribution of baseline characteristics; b Among postmenopausal women; c among women with at least one completed term pregnancy; d non-localized breast cancer includes regional (n = 401), distant (n = 15), and unspecified (n = 108) metastatic sites; e time between diagnosis and end of follow-up; f Time between diagnosis and death, among those who died of any cause; g Time between diagnosis and death, among those who died of breast cancer. * Missing data: Age at menarche: 36 cases (1.8%); age at menopause: 477 cases (31%); ever FTP: 30 cases (1.5%); age at first FTP: 7 cases (0.4%); PR status: 528 cases (26%); breast cancer stage: 393 cases (19.6%)
\